Clinical Trial Update: Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C) [Phase 2]

View source ↗

Summary

Phase 2 study of MK-3475 (pembrolizumab) in MSI-positive and MSI-negative colorectal cancer and MSI-positive non-colorectal cancers has completed with results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Non-colorectal Cancer

Drugs mentioned

• MK-3475 (pembrolizumab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: MSI Positive Colorectal Cancer, MSI Negative Colorectal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-01-07